Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
August 27, 2021updated 04 Jan 2022 11:30am

Q2 2021 saw a 61% drop in clinical trial terminations and suspensions globally

By Carmen

The medical device clinical trial terminations and suspensions in Q2 2021 saw a 61% decrease globally when compared with the last four – quarters average, according to GlobalData’s medical devices database.

The global medical devices market was worth $479.03bn in 2020 and is expected to reach $531.77bn by 2023, according to GlobalData’s analysis.

 

 

Medical devices clinical trials by market: General Surgery has the most terminations and suspensions

Looking at the clinical trial terminations and suspensions by the type of markets, General Surgery accounted for the largest proportion (14%) in Q2 2021, followed by Cardiovascular Devices (13%) and Neurology Devices (12%).

Of the global medical devices market value, the General Surgery market held a 10% share worth $49bn in 2020 and is expected to reach $63.76bn by 2023.

 

 

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

North America tops terminated and suspended trials activity

Comparing medical device clinical trial terminations and suspensions in different regions of the globe, North America held the top position with a 41% share during Q2 2021, followed by Europe with 31%, and Asia-Pacific with 16%.

On a country level, the US had the largest share (25%) of the global clinical trial terminations and suspensions during the quarter. In second place was United Kingdom with a share of 5%, followed by Germany with 5%.

 

 



Looking at the share of activity of sponsored clinical trials in terms of terminations and suspensions, company-sponsored trials accounted for a 43% share, while institute-sponsored trials held the remaining share.

The quarterly average for the last four quarters saw company-sponsored trials account for 41% of terminations and suspensions, while institute-sponsored trials account for 59%.

Methodology
The clinical trials data used for the analysis were extracted from the medical Clinical Trials Database of GlobalData’s Medical Intelligence Center. Medical device clinical trials database covers all clinical trials conducted on medical devices, combination devices, diagnostics, and diagnostic imaging agents covering 16 markets (as per medical device taxonomy). GlobalData tracks clinical trials from six key registries: NCT, UMIN, ACTRN, ChiCTR, EudraCT, and ISRCT. It also monitors universities, company websites, press releases, investor presentations and annual reports to track medical device clinical trials. Industry refers to commercial entities such as private and public companies and their subsidiaries. Non-Industry refers to non-profit making entities including hospitals, universities, government research institutions and non-government research institutions. The information is collected by following systematic research techniques and proprietary methodology. Only terminated, suspended and withdrawn clinical trials are considered for this analysis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU